Document is current
Any future updates will be listed below
-
Authors
Nezu, Tomohisa https://orcid.org/0000-0003-4877-2336
Eto, Futoshi
Hironaka, Akemi
Aoki, Shiro
Neshige, Shuichiro
Tasaka, Saki
Kirimoto, Hikari
Maruyama, Hirofumi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science KAKENHI (20K16579, 21K10210, 22H03454, 23H02827)
Nakatomi Foundation
Hiroshima University
- License Information
-
More Information
Article History
Received: 3 May 2024
Accepted: 10 June 2024
First Online: 29 July 2024
Declarations
:
: Dr. Maruyama received Grants-in-Aid for Scientific Research (23H02827) and research support from Eisai, Takeda Pharmaceutical, Otsuka Pharmaceutical, Nihon Pharmaceutical, Shionogi, Teijin Pharma, Fuji Film, Sumitomo Pharma, Nihon Medi-Physics, Daiichi Sankyo, Kyowa Kirin, Sanofi, Novartis, Tsumura, Japan Blood Products Organization, Chugai Pharmaceutical, Mitsubishi Tanabe Pharma, and Viatris, which are unrelated to the submitted work. All other authors declare that they have no conflicts of interest.
: The study conformed to the Declaration of Helsinki and was approved by the ethics committees at Hiroshima University, including the institutional review board (approval number E2023-0201). This study was performed under the opt-out method, as it was performed using clinical records.
: Informed consent for participation was not obtained from the participants.
